Prevent contamination with small-scale, sterile connections for single-use R&D and PD processing
AseptiQuik® connectors from CPC provide easy and reliable sterile connections for single-use biopharmaceutical processing. Robust designs for 1/8” (3.2mm) to 1” (26.4mm) quickly transfer valuable media. Download our Q&A.
AseptiQuik® connectors from CPC make it easy to create closed bioprocessing systems for low-volume applications such as R&D and product development. With robust, easy-to-use sterile connector designs for tubing as small as 3.2mm (1/8”), our connectors enable technicians to transfer media with more confidence and reduced risk of biological contamination and cross-contamination.
For even greater flexibility in R&D settings, CPC offers combination connectors that enable easy connections between hybrid stainless steel and single-use processing. The AseptiQuik STC connector combines an AseptiQuik sterile connector with a Steam-Thru® II SIP connection that can be mounted directly to a stainless steel vessel via a sanitary termination.
CPC’s sterile connection technologies include genderless AseptiQuik connectors that simplify single-use systems design and process integration and are available in sizes ranging from 6.4mm to 19.0mm (1/4” to 3/4”). Because the connectors are interchangeable-any single-use G series connector mates with any other G series connector-systems are more flexible and minimize supply chain complexity.
The AseptiQuik family offers the broadest range of single-use sterile connectors in the industry, with flow configurations from 3.2mm to 25.4mm (1/8” to 1”). For more information on closed systems for small-scale processes, download our Q&A.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
